Literature DB >> 20233968

Mast cell proteases: multifaceted regulators of inflammatory disease.

Gunnar Pejler1, Elin Rönnberg, Ida Waern, Sara Wernersson.   

Abstract

Mast cells (MCs) are currently receiving increased attention among the scientific community, largely because of the recent identification of crucial functions for MCs in a variety of disorders. However, it is in many cases not clear exactly how MCs contribute in the respective settings. MCs express extraordinarily high levels of a number of proteases of chymase, tryptase, and carboxypeptidase A type, and these are stored in high amounts as active enzymes in the MC secretory granules. Hence, MC degranulation leads to the massive release of fully active MC proteases, which probably have a major impact on any condition in which MC degranulation occurs. Indeed, the recent generation and evaluation of mouse strains lacking individual MC proteases have indicated crucial contributions of these to a number of different disorders. MC proteases may thus account for many of the effects ascribed to MCs and are currently emerging as promising candidates for treatment of MC-driven disease. In this review, we discuss these findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233968     DOI: 10.1182/blood-2010-01-257287

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  128 in total

1.  Lymph node fibroblastic reticular cells deposit fibrosis-associated collagen following organ transplantation.

Authors:  Xiaofei Li; Jing Zhao; Vivek Kasinath; Mayuko Uehara; Liwei Jiang; Naima Banouni; Martina M McGrath; Takaharu Ichimura; Paolo Fiorina; Dario R Lemos; Su Ryon Shin; Carl F Ware; Jonathan S Bromberg; Reza Abdi
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  Characterization of Mast Cell Activation Syndrome.

Authors:  Lawrence B Afrin; Sally Self; Jeremiah Menk; John Lazarchick
Journal:  Am J Med Sci       Date:  2016-12-16       Impact factor: 2.378

Review 3.  Biological implications of preformed mast cell mediators.

Authors:  Anders Lundequist; Gunnar Pejler
Journal:  Cell Mol Life Sci       Date:  2010-11-11       Impact factor: 9.261

4.  A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granule-mediated pathway.

Authors:  Fabio Rabelo Melo; Ida Waern; Elin Rönnberg; Magnus Åbrink; David M Lee; Susan M Schlenner; Thorsten B Feyerabend; Hans-Reimer Rodewald; Boris Turk; Sara Wernersson; Gunnar Pejler
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

Review 5.  Chymase inhibition as a pharmacological target: a role in inflammatory and functional gastrointestinal disorders?

Authors:  S Heuston; N P Hyland
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 6.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

7.  Heparan sulfate 6-O-sulfotransferase isoform-dependent regulatory effects of heparin on the activities of various proteases in mast cells and the biosynthesis of 6-O-sulfated heparin.

Authors:  Md Ferdous Anower-E-Khuda; Hiroko Habuchi; Naoko Nagai; Osami Habuchi; Takashi Yokochi; Koji Kimata
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

8.  The chymase mouse mast cell protease 4 degrades TNF, limits inflammation, and promotes survival in a model of sepsis.

Authors:  Adrian M Piliponsky; Ching-Cheng Chen; Eon J Rios; Piper M Treuting; Asha Lahiri; Magnus Abrink; Gunnar Pejler; Mindy Tsai; Stephen J Galli
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

Review 9.  Mast cell chymase and tryptase in abdominal aortic aneurysm formation.

Authors:  Yi Wang; Guo-Ping Shi
Journal:  Trends Cardiovasc Med       Date:  2012-08-14       Impact factor: 6.677

10.  Granzyme D is a novel murine mast cell protease that is highly induced by multiple pathways of mast cell activation.

Authors:  Elin Rönnberg; Gabriela Calounova; Bengt Guss; Anders Lundequist; Gunnar Pejler
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.